The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Checkpoint Inhibitors for Treating Cancer Market Research Report 2024
Synopsis
Checkpoint inhibitors for treating cancer is a type of drug that blocks certain proteins made by some types of immune system cells, such as T cells, and some cancer cells. These proteins help keep immune responses in check and can keep T cells from killing cancer cells. When these proteins are blocked, the “brakes” on the immune system are released and T cells are able to kill cancer cells better. Examples of checkpoint proteins found on T cells or cancer cells include PD-1/PD-L1 and CTLA-4/B7-1/B7-2.
The global Checkpoint Inhibitors for Treating Cancer market was valued at US$ 12490 million in 2023 and is anticipated to reach US$ 62650 million by 2030, witnessing a CAGR of 25.6% during the forecast period 2024-2030.
The major players in global Checkpoint Inhibitors for Treating Cancer market include Bristol-Myers Squibb(BMS), Merck, etc., and the market concentration rate is high. North America is the main market, and occupies about 95% of the global market. PD-1 Inhibitors is the main type, with a share about 80%. Melanoma Treatment is the main application, which holds a share about 80%.
This report aims to provide a comprehensive presentation of the global market for Checkpoint Inhibitors for Treating Cancer, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Checkpoint Inhibitors for Treating Cancer.
Report Scope
The Checkpoint Inhibitors for Treating Cancer market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Checkpoint Inhibitors for Treating Cancer market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Checkpoint Inhibitors for Treating Cancer manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Bristol-Myers Squibb(BMS)
Merck
Roche
Segment by Type
PD-1 Inhibitors
PD-L1 Inhibitors
CTLA-4 Inhibitors
Segment by Application
Melanoma Treatment
Bladder Cancer Treatment
Other
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Checkpoint Inhibitors for Treating Cancer manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Checkpoint Inhibitors for Treating Cancer in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Checkpoint inhibitors for treating cancer is a type of drug that blocks certain proteins made by some types of immune system cells, such as T cells, and some cancer cells. These proteins help keep immune responses in check and can keep T cells from killing cancer cells. When these proteins are blocked, the “brakes” on the immune system are released and T cells are able to kill cancer cells better. Examples of checkpoint proteins found on T cells or cancer cells include PD-1/PD-L1 and CTLA-4/B7-1/B7-2.
The global Checkpoint Inhibitors for Treating Cancer market was valued at US$ 12490 million in 2023 and is anticipated to reach US$ 62650 million by 2030, witnessing a CAGR of 25.6% during the forecast period 2024-2030.
The major players in global Checkpoint Inhibitors for Treating Cancer market include Bristol-Myers Squibb(BMS), Merck, etc., and the market concentration rate is high. North America is the main market, and occupies about 95% of the global market. PD-1 Inhibitors is the main type, with a share about 80%. Melanoma Treatment is the main application, which holds a share about 80%.
This report aims to provide a comprehensive presentation of the global market for Checkpoint Inhibitors for Treating Cancer, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Checkpoint Inhibitors for Treating Cancer.
Report Scope
The Checkpoint Inhibitors for Treating Cancer market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Checkpoint Inhibitors for Treating Cancer market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Checkpoint Inhibitors for Treating Cancer manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Bristol-Myers Squibb(BMS)
Merck
Roche
Segment by Type
PD-1 Inhibitors
PD-L1 Inhibitors
CTLA-4 Inhibitors
Segment by Application
Melanoma Treatment
Bladder Cancer Treatment
Other
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Checkpoint Inhibitors for Treating Cancer manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Checkpoint Inhibitors for Treating Cancer in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Index1 Checkpoint Inhibitors for Treating Cancer Market Overview
1.1 Product Overview and Scope of Checkpoint Inhibitors for Treating Cancer
1.2 Checkpoint Inhibitors for Treating Cancer Segment by Type
1.2.1 Global Checkpoint Inhibitors for Treating Cancer Market Value Comparison by Type (2024-2030)
1.2.2 PD-1 Inhibitors
1.2.3 PD-L1 Inhibitors
1.2.4 CTLA-4 Inhibitors
1.3 Checkpoint Inhibitors for Treating Cancer Segment by Application
1.3.1 Global Checkpoint Inhibitors for Treating Cancer Market Value by Application: (2024-2030)
1.3.2 Melanoma Treatment
1.3.3 Bladder Cancer Treatment
1.3.4 Other
1.4 Global Checkpoint Inhibitors for Treating Cancer Market Size Estimates and Forecasts
1.4.1 Global Checkpoint Inhibitors for Treating Cancer Revenue 2019-2030
1.4.2 Global Checkpoint Inhibitors for Treating Cancer Sales 2019-2030
1.4.3 Global Checkpoint Inhibitors for Treating Cancer Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Checkpoint Inhibitors for Treating Cancer Market Competition by Manufacturers
2.1 Global Checkpoint Inhibitors for Treating Cancer Sales Market Share by Manufacturers (2019-2024)
2.2 Global Checkpoint Inhibitors for Treating Cancer Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Checkpoint Inhibitors for Treating Cancer Average Price by Manufacturers (2019-2024)
2.4 Global Checkpoint Inhibitors for Treating Cancer Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Checkpoint Inhibitors for Treating Cancer, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Checkpoint Inhibitors for Treating Cancer, Product Type & Application
2.7 Checkpoint Inhibitors for Treating Cancer Market Competitive Situation and Trends
2.7.1 Checkpoint Inhibitors for Treating Cancer Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Checkpoint Inhibitors for Treating Cancer Players Market Share by Revenue
2.7.3 Global Checkpoint Inhibitors for Treating Cancer Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Checkpoint Inhibitors for Treating Cancer Retrospective Market Scenario by Region
3.1 Global Checkpoint Inhibitors for Treating Cancer Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Checkpoint Inhibitors for Treating Cancer Global Checkpoint Inhibitors for Treating Cancer Sales by Region: 2019-2030
3.2.1 Global Checkpoint Inhibitors for Treating Cancer Sales by Region: 2019-2024
3.2.2 Global Checkpoint Inhibitors for Treating Cancer Sales by Region: 2025-2030
3.3 Global Checkpoint Inhibitors for Treating Cancer Global Checkpoint Inhibitors for Treating Cancer Revenue by Region: 2019-2030
3.3.1 Global Checkpoint Inhibitors for Treating Cancer Revenue by Region: 2019-2024
3.3.2 Global Checkpoint Inhibitors for Treating Cancer Revenue by Region: 2025-2030
3.4 North America Checkpoint Inhibitors for Treating Cancer Market Facts & Figures by Country
3.4.1 North America Checkpoint Inhibitors for Treating Cancer Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Checkpoint Inhibitors for Treating Cancer Sales by Country (2019-2030)
3.4.3 North America Checkpoint Inhibitors for Treating Cancer Revenue by Country (2019-2030)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Checkpoint Inhibitors for Treating Cancer Market Facts & Figures by Country
3.5.1 Europe Checkpoint Inhibitors for Treating Cancer Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Checkpoint Inhibitors for Treating Cancer Sales by Country (2019-2030)
3.5.3 Europe Checkpoint Inhibitors for Treating Cancer Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Checkpoint Inhibitors for Treating Cancer Market Facts & Figures by Country
3.6.1 Asia Pacific Checkpoint Inhibitors for Treating Cancer Market Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Checkpoint Inhibitors for Treating Cancer Sales by Country (2019-2030)
3.6.3 Asia Pacific Checkpoint Inhibitors for Treating Cancer Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.7 Latin America Checkpoint Inhibitors for Treating Cancer Market Facts & Figures by Country
3.7.1 Latin America Checkpoint Inhibitors for Treating Cancer Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Checkpoint Inhibitors for Treating Cancer Sales by Country (2019-2030)
3.7.3 Latin America Checkpoint Inhibitors for Treating Cancer Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Checkpoint Inhibitors for Treating Cancer Market Facts & Figures by Country
3.8.1 Middle East and Africa Checkpoint Inhibitors for Treating Cancer Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Checkpoint Inhibitors for Treating Cancer Sales by Country (2019-2030)
3.8.3 Middle East and Africa Checkpoint Inhibitors for Treating Cancer Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Checkpoint Inhibitors for Treating Cancer Sales by Type (2019-2030)
4.1.1 Global Checkpoint Inhibitors for Treating Cancer Sales by Type (2019-2024)
4.1.2 Global Checkpoint Inhibitors for Treating Cancer Sales by Type (2025-2030)
4.1.3 Global Checkpoint Inhibitors for Treating Cancer Sales Market Share by Type (2019-2030)
4.2 Global Checkpoint Inhibitors for Treating Cancer Revenue by Type (2019-2030)
4.2.1 Global Checkpoint Inhibitors for Treating Cancer Revenue by Type (2019-2024)
4.2.2 Global Checkpoint Inhibitors for Treating Cancer Revenue by Type (2025-2030)
4.2.3 Global Checkpoint Inhibitors for Treating Cancer Revenue Market Share by Type (2019-2030)
4.3 Global Checkpoint Inhibitors for Treating Cancer Price by Type (2019-2030)
5 Segment by Application
5.1 Global Checkpoint Inhibitors for Treating Cancer Sales by Application (2019-2030)
5.1.1 Global Checkpoint Inhibitors for Treating Cancer Sales by Application (2019-2024)
5.1.2 Global Checkpoint Inhibitors for Treating Cancer Sales by Application (2025-2030)
5.1.3 Global Checkpoint Inhibitors for Treating Cancer Sales Market Share by Application (2019-2030)
5.2 Global Checkpoint Inhibitors for Treating Cancer Revenue by Application (2019-2030)
5.2.1 Global Checkpoint Inhibitors for Treating Cancer Revenue by Application (2019-2024)
5.2.2 Global Checkpoint Inhibitors for Treating Cancer Revenue by Application (2025-2030)
5.2.3 Global Checkpoint Inhibitors for Treating Cancer Revenue Market Share by Application (2019-2030)
5.3 Global Checkpoint Inhibitors for Treating Cancer Price by Application (2019-2030)
6 Key Companies Profiled
6.1 Bristol-Myers Squibb(BMS)
6.1.1 Bristol-Myers Squibb(BMS) Corporation Information
6.1.2 Bristol-Myers Squibb(BMS) Description and Business Overview
6.1.3 Bristol-Myers Squibb(BMS) Checkpoint Inhibitors for Treating Cancer Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Bristol-Myers Squibb(BMS) Checkpoint Inhibitors for Treating Cancer Product Portfolio
6.1.5 Bristol-Myers Squibb(BMS) Recent Developments/Updates
6.2 Merck
6.2.1 Merck Corporation Information
6.2.2 Merck Description and Business Overview
6.2.3 Merck Checkpoint Inhibitors for Treating Cancer Sales, Revenue and Gross Margin (2019-2024)
6.2.4 Merck Checkpoint Inhibitors for Treating Cancer Product Portfolio
6.2.5 Merck Recent Developments/Updates
6.3 Roche
6.3.1 Roche Corporation Information
6.3.2 Roche Description and Business Overview
6.3.3 Roche Checkpoint Inhibitors for Treating Cancer Sales, Revenue and Gross Margin (2019-2024)
6.3.4 Roche Checkpoint Inhibitors for Treating Cancer Product Portfolio
6.3.5 Roche Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Checkpoint Inhibitors for Treating Cancer Industry Chain Analysis
7.2 Checkpoint Inhibitors for Treating Cancer Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Checkpoint Inhibitors for Treating Cancer Production Mode & Process
7.4 Checkpoint Inhibitors for Treating Cancer Sales and Marketing
7.4.1 Checkpoint Inhibitors for Treating Cancer Sales Channels
7.4.2 Checkpoint Inhibitors for Treating Cancer Distributors
7.5 Checkpoint Inhibitors for Treating Cancer Customers
8 Checkpoint Inhibitors for Treating Cancer Market Dynamics
8.1 Checkpoint Inhibitors for Treating Cancer Industry Trends
8.2 Checkpoint Inhibitors for Treating Cancer Market Drivers
8.3 Checkpoint Inhibitors for Treating Cancer Market Challenges
8.4 Checkpoint Inhibitors for Treating Cancer Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
